Home Alzheimer’s Disease Rana R. McKay, MD, on the Impact of the Phase II OMNIVORE...

Rana R. McKay, MD, on the Impact of the Phase II OMNIVORE Trial

Nivolumab (Opdivo) plus ipilumumab (Yervoy) is the established first-line treatment for advanced renal cell carcinoma (RCC), but optimal duration of nivolumab and sequencing for ipilumumab remains unclear. Results from the response-based phase II OMNIVORE study, presented during the 2020 ASCO Virtual Scientific Program, demonstrated that delayed treatment with ipilumumab is insufficient to achieve a response in patients with RCC.

In an interview with CancerNetwork, Rana R. McKay, MD of the University of California San Diego discusses the impact of these findings, and what it may mean for practicing clinicians.

 

Transcription:

So, with regards to the impact of this study, you know, many individuals, out in clinical practice in the community are faced with patients before them and are constantly asking the question of balancing risk and toxicity. Does everybody need to get…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments